Easton Pharmaceuticals Announces It Has Engaged Online Marketing & Branding Specialists to Support the Firm's Updated Product...
March 19 2014 - 8:42AM
Marketwired
Easton Pharmaceuticals Announces It Has Engaged Online Marketing
and Branding Specialists to Support the Firm's Updated Products,
Branding and Website Launch; Provides Update on Its Medical
Marijuana Initiatives
TORONTO, ONTARIO--(Marketwired - Mar 19, 2014) - Easton
Pharmaceuticals Inc. (OTC: EAPH), a specialty pharmaceutical
company that owns, designs, develops, and markets an array of
topically-delivered drugs and therapeutic / cosmetic healthcare
products, today announces it has hired marketing and branding
specialists to support the firms brand and online marketing
awareness, as well as provide an update on its medical marijuana
initiatives.
Easton Pharmaceuticals has recognized that its website, online
marketing strategy and branding needed improving. As a result,
Easton has engaged the services of a leading Toronto-based branding
agency who have established itself in the industry with being able
to assist companies such as Easton Pharmaceuticals to gain brand
recognition while possessing strong sales and marketing skills to
effectively promote the company's products and website awareness.
The company utilizes some of the most proficient digital solutions
managers for website development. Easton Pharmaceuticals has been
in the process of revamping the company's website which is expected
to be online no later than the beginning of next week which will
also eventually allow the company's products to be purchased
directly through its website. In addition, Easton is revamping its
product line which includes packaging, naming of products,
brochures and literature which will be showcased on the company's
updated website, set to be unveiled in the next few days.
In other developments, Easton Pharmaceuticals, as previously
stated by the company, is presently in the process of drafting and
executing, through their respective attorneys, a final definitive
agreement towards its Medical Marijuana Initiatives. The Company
apologizes for the many delays, but most have not been in the
control of the company. Easton has been in negotiations with
various companies, some of which have been disclosed, which has now
been narrowed down to a joint partnership for the intended
acquisition of up to 3 companies and property who have applied for
MMPR licenses for all of Canada, been granted an approval to build
out what are considered very large facilities as mandated per MMPR
regulations and have been growing Marijuana for current
dispensaries including the supplying of Marijuana for Research
& Development to various institutions. All of which have added
to the complexity of the negotiations. Easton Pharmaceuticals
believes its patented transdermal delivery system can one day in
the near future be used to administer drugs for the treatment of
various ailments and conditions utilizing certain agents derived
from Marijuana. As stated, it is the company's full intention on
utilizing its cash position towards an acceptable agreement to
enter into what is believed to be the bourgeoning medical marijuana
industry.
About Easton Pharmaceuticals Easton Pharmaceuticals is a
specialty pharmaceutical company involved in various industries
including medical marijuana who also owns, designs, develops, and
markets topically-delivered drugs and therapeutic / cosmetic
healthcare products, focused on cancer and other health issues
related towards male and female sexual dysfunction, wound healing,
pain, motion sickness, scar and stretch marks, cellulite, varicose
veins and other conditions. The company's gel formulation is
thought to be an innovative and unique transdermal delivery system.
Easton Pharmaceuticals product "VIORRA", is an
over-the-counter aid for the treatment to restore and improve
vaginal moisture and elasticity which is believed to have a
positive effect on women's sexual desire and arousal, FSAD (Female
Sexual Arousal Disorder) the world market for these female
conditions are conservatively estimated to be in the billions.
VIORRA is a topical, daily-use product classified by the
FDA as containing Generally Recognized as Safe
ingredients.
For More Information Visit:
http://www.ashleybiomedical.com &
http://www.eastonpharmaceuticalsinc.com
Safe Harbor
This news release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(The "Act"). In particular, when used in the preceding of
discussion, the words "anticipate," "pleased," "plan," "confident
that," "believe," "expect," "possible" or "intent to" and similar
conditional expressions are intended to identify forward-looking
statements within the meaning of the Act and are subject to the
safe harbor created by the Act. Such statements are subject to
certain risks and uncertainties and actual results could differ
materially from those expressed in any of the forward-looking
statements. Such risks and uncertainties include, but are not
limited to, market conditions, general acceptance of the company's
products and technologies, competitive factors, the ability to
successfully complete additional or adequate financing, government
approvals or changes to proposed laws and other risks and
uncertainties further stated in the company's financial reports and
filings.
Contact: Carla Pepe Easton Pharmaceuticals Inc. Tel: +1(416)
619-0291 Tel: +1(347) 284-0192 email:
info@eastonpharmaceuticalsinc.com email:
info@ashleybiomedical.com
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Easton Pharmaceuticals (CE) (USOTC:EAPH)
Historical Stock Chart
From Apr 2023 to Apr 2024